{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lyme-disease/prescribing-information/doxycycline/","result":{"pageContext":{"chapter":{"id":"10094473-f953-57de-8453-10fc5a4709a2","slug":"doxycycline","fullItemName":"Doxycycline","depth":2,"htmlHeader":"<!-- begin field acbcca15-b970-49d7-82e6-cc223b5c993d --><h2>Doxycycline</h2><!-- end field acbcca15-b970-49d7-82e6-cc223b5c993d -->","summary":"","htmlStringContent":"<!-- begin item 249d5821-7201-441d-8634-e2cf1016794b --><!-- end item 249d5821-7201-441d-8634-e2cf1016794b -->","topic":{"id":"56ba86e1-b79d-5c00-948b-65c581b69f79","topicId":"7aa291ec-f53e-44b9-8a66-e9b4ee6a577f","topicName":"Lyme disease","slug":"lyme-disease","lastRevised":"Last revised in August 2019","chapters":[{"id":"5995c194-77ea-5203-83e7-86b64985db74","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cc168196-a2da-5a8f-873c-fb75c4c3960f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a8622b23-7f1f-543b-b5ba-e9f4c9547c1c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4c25a599-a26d-5702-b9f6-43dff73c83c8","slug":"changes","fullItemName":"Changes"},{"id":"29379f04-710e-5ce7-ba07-ea9a1e178ac7","slug":"update","fullItemName":"Update"}]},{"id":"bc55cfd2-4253-598a-8be1-54061ce22b6a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"49a7229f-6129-58a8-9b6e-7471ccde1b15","slug":"goals","fullItemName":"Goals"},{"id":"ca83767e-8bdd-5ab2-b78a-c8577ab6da08","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"928ab402-0b5e-53b7-96d3-a64275903911","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5230b0a-b405-5725-9a8a-95f4a63239e1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a9b48f27-60ba-54c9-9deb-e1ce41732fc9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5cc0f690-6775-5131-a1fc-75d9efa0b535","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8bbfecb1-6cb7-511b-9697-7915788a4bff","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"1c94f9ce-3656-59d3-86ed-d515d113270a","slug":"definition","fullItemName":"Definition"},{"id":"1a4679d0-b6d3-5b97-917c-5d08de1be33b","slug":"causes","fullItemName":"Causes"},{"id":"6e585a22-8dfe-578a-99a9-1be143896b7f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e1ded21e-6325-5c18-ae0a-6b540cd28c19","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"126215ba-45c3-5bbf-ae98-2fff7bb1ed89","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5240144c-4a60-5d30-ab1e-63d4f2995a2f","slug":"complications","fullItemName":"Complications"},{"id":"a5092448-11ae-5b17-8a6b-8b6f6d5b80cf","slug":"other-tick-borne-diseases","fullItemName":"Other tick-borne diseases"}]},{"id":"d2ae2f81-2546-5ff8-8002-577ff4741f57","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0cf6a4b7-b848-5424-b311-ae2e70bf1cf4","slug":"when-to-suspect-lyme-disease","fullItemName":"When to suspect Lyme disease"},{"id":"868a26b1-1742-50d5-8576-14ab327a0c64","slug":"differential-diagnosis-erythema-migrans","fullItemName":"Differential diagnosis (erythema migrans)"}]},{"id":"1a2edd0e-8cc2-5cce-aa6f-5519b5f40775","fullItemName":"Management","slug":"management","subChapters":[{"id":"35e8dbb5-da7f-5fd3-9ff3-b9926f24ed6e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"8d378757-a1b8-5c8c-95b4-d1428557dcb3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"10094473-f953-57de-8453-10fc5a4709a2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"714c78fe-f533-5abf-8ab9-28bdb2658044","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"245cb0af-f052-5aa2-8912-6e553063438e","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"98b0aa55-4436-555a-bfde-05ef12f03083","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0edcddd4-56b7-5124-b56a-14f7a38f3fd5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d42dec32-1352-5fb5-8d7d-c3591bae0448","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"254e7467-a025-51bb-849c-803edae01e3b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"659f6620-1672-5b1d-bf3e-891ce69b4ff1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fdc13e77-5b9e-59a9-b651-15a5e1b1f333","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ccedf4e2-7c6a-5251-abee-5f5f14e5ed39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a2095079-fcfd-5a3f-85e9-d631c57dd891","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8d378757-a1b8-5c8c-95b4-d1428557dcb3","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2bf891f6-9c01-5e2f-85fc-125933d20b0b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field ae7f463f-8eff-48c2-bcce-ba20a2c932f8 --><h3>Contraindications and cautions</h3><!-- end field ae7f463f-8eff-48c2-bcce-ba20a2c932f8 -->","summary":"","htmlStringContent":"<!-- begin item 1e4942ae-50ef-4c6a-8be6-4d744191bf08 --><!-- begin field 1fddfb35-3371-43fd-b648-a362d3e4ff23 --><ul><li><strong>Do not prescribe doxycyline to:</strong><ul><li>Pregnant or breastfeeding women and children under 12 years of age as it is deposited in the teeth and bones of unborn or developing children.</li><li>People with:<ul><li>Known hypersensitivity to any of the tetracyclines.</li><li>Acute porphyria.</li><li>Systemic lupus erythematous — tetracyclines may exacerbate systemic lupus erythematosus.</li></ul></li></ul></li><li>Prescribe doxycyline with caution in people with myasthenia gravis — tetracyclines may increase muscle weakness in people with myasthenia gravis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">BNF 68, 2014</a>]</p><!-- end field 1fddfb35-3371-43fd-b648-a362d3e4ff23 --><!-- end item 1e4942ae-50ef-4c6a-8be6-4d744191bf08 -->","subChapters":[]},{"id":"b22946e6-1f98-571b-8708-b28746ba57f2","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field db6720df-8d27-452d-8dc5-4ba9cee22044 --><h3>Adverse effects</h3><!-- end field db6720df-8d27-452d-8dc5-4ba9cee22044 -->","summary":"","htmlStringContent":"<!-- begin item 956eb2aa-cfb8-4606-9dcf-9eb6f37e78eb --><!-- begin field b5070cd0-c5af-4f89-b052-fab77df05d27 --><ul><li><strong>Blood disorders</strong> — haemolytic anaemia, thrombocytopenia, neutropenia, eosinophilia (frequency unknown).</li><li><strong>Gastrointestinal</strong> — nausea, vomiting (common), dyspepsia (uncommon), abdominal discomfort, diarrhoea, tooth discolouration and enamel hypoplasia in children (frequency unknown).<ul><li><strong>Rarely:</strong> dysphagia, oesophagitis, oesophageal irritation, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Hepatic disorders</strong> – hepatotoxicity, hepatitis, jaundice, hepatic failure (frequency unknown).</li><li><strong>Renal disorders</strong> — blood urea increased.</li><li><strong>Skin</strong> — photosensitivity, rash (common).<ul><li><strong>Rarely</strong>: toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, erythema multiforme, exfoliative dermatitis, drug reaction with eosinophilia and systemic symptoms (DRESS).</li></ul></li><li><strong>Other rare adverse effects include: </strong><ul><li>Anaphylaxis.</li><li>Arthralgia, myalgia.</li><li>Bulging fontanelles in infants.</li><li>Flushing.</li><li>Severe headache and/or visual disturbances — may be an early symptom of benign intracranial hypertension, a rare but serious adverse effect. If this occurs the drug should be stopped immediately.</li><li>Tinnitus.</li></ul></li><li><strong>A Jarisch-Herxheimer reaction </strong>— this has been observed in about 15% of people with Lyme disease. It is a systemic reaction thought to be caused by the release of cytokines when antibiotics kill large numbers of bacteria. Symptoms include a worsening of fever, chills, muscle pains and headache. It may be mistaken for an allergic reaction and the person may stop their antibiotics. The reaction can start between 1–12 hours after antibiotics are started, but can also occur later and can last for a few hours or 1–2 days. The reaction is self-limiting and usually resolves within 24 to 48 hours. Provided the symptoms are not severe and there is no evidence of an allergic reaction (such as urticaria), the person can be advised to continue the antibiotic.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">Dubrey et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">NICE, 2018a</a>]</p><!-- end field b5070cd0-c5af-4f89-b052-fab77df05d27 --><!-- end item 956eb2aa-cfb8-4606-9dcf-9eb6f37e78eb -->","subChapters":[]},{"id":"b25306f5-0354-54d2-8d77-173b155d2960","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 46e1323b-b806-41ad-8882-2fbf3513dfc0 --><h3>Drug interactions</h3><!-- end field 46e1323b-b806-41ad-8882-2fbf3513dfc0 -->","summary":"","htmlStringContent":"<!-- begin item dd742779-9bb5-49a7-8300-b53a946cd067 --><!-- begin field aefa91ac-5cd9-4ff5-b0cb-9a43e444ee66 --><ul><li><strong>Antacids (containing aluminium, bismuth, calcium, or magnesium) and other medications containing iron or zinc</strong> — these reduce the absorption of tetracyclines if taken concurrently.<ul><li>Avoid taking antacids and other medications containing iron or zinc, 2 hours before or after taking tetracyclines.</li></ul></li><li><strong>CYP3A enzyme inducers</strong> (phenobarbital, carbamazepine or phenytoin) — these may reduce the serum half-life of doxycycline. Monitor and adjust the dose if necessary.</li><li><strong>Insulin </strong>— the blood-glucose lowering effect may be increased if taken with doxycycline. Monitor blood-glucose levels.</li><li><strong>Lithium</strong> — levels may be increased by doxycycline. Consider increasing the frequency of lithium monitoring.</li><li><strong>Methotrexate</strong> — levels may be increased by doxycycline.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of doxycycline.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li><li><strong>Retinoids </strong>— there is a possible increased risk of benign intracranial pressure if tetracyclines are used concurrently with retinoids (such as isotretinoin).<ul><li>Avoid the concurrent use of tetracyclines and retinoids.</li></ul></li><li><strong>Rifampicin</strong> — doxycycline levels are markedly reduced, which may lead to treatment failure. Monitor the effects and increase doxycycline dose if necessary.</li><li><strong>Warfarin </strong>— the concurrent use of warfarin with tetracyclines may increase the anticoagulant effect. However, there is little evidence to suggest clinical relevance.<ul><li>Consider monitoring the person's international normalized ratio (INR) regularly and within 3 days of starting the tetracycline. Adjust the warfarin dose accordingly.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">BNF 75, 2018</a>]</p><!-- end field aefa91ac-5cd9-4ff5-b0cb-9a43e444ee66 --><!-- end item dd742779-9bb5-49a7-8300-b53a946cd067 -->","subChapters":[]},{"id":"d8e097f2-42aa-56ac-92a8-62bcea252c60","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 5c5efc88-8af4-47cc-b9b8-72a30aa6cfc9 --><h3>Pregnancy and breastfeeding</h3><!-- end field 5c5efc88-8af4-47cc-b9b8-72a30aa6cfc9 -->","summary":"","htmlStringContent":"<!-- begin item 11d31f8d-19a6-4043-8bca-2310a25720cb --><!-- begin field a3cc6161-a25f-4331-ac21-a6f3a7f9d219 --><h4>Pregnancy</h4><ul><li>Doxycycline is contraindicated in women who are pregnant.<ul><li>Tetracyclines may be considered in the first trimester if required urgently and no suitable alternatives with a better safety profile are available.</li></ul></li></ul><h4>Breastfeeding</h4><ul><li>Doxycycline is contraindicated in women who are breastfeeding.<ul><li>However, concerns about bone deposition of tetracyclines and possible staining of infant’s dental enamel have not been confirmed, and are unlikely during short-term use. Absorption by the infant is also inhibited by calcium in the breastmilk.</li></ul></li><li>If other antibiotics are not appropriate, tetracycline is the preferred drug from this group. Short-term use (less than 3 weeks duration) is acceptable for most tetracyclines. Long-term use is not advisable.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">Fenner, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">NPIS, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lyme-disease/references/\">BNF 75, 2018</a>] </p><!-- end field a3cc6161-a25f-4331-ac21-a6f3a7f9d219 --><!-- end item 11d31f8d-19a6-4043-8bca-2310a25720cb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}